273 related articles for article (PubMed ID: 21448722)
1. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research.
Han ME; Jeon TY; Hwang SH; Lee YS; Kim HJ; Shim HE; Yoon S; Baek SY; Kim BS; Kang CD; Oh SO
Cell Mol Life Sci; 2011 Nov; 68(21):3589-605. PubMed ID: 21448722
[TBL] [Abstract][Full Text] [Related]
2. CD24+CD44+CD54+EpCAM+ gastric cancer stem cells predict tumor progression and metastasis: clinical and experimental evidence.
Gómez-Gallegos AA; Ramírez-Vidal L; Becerril-Rico J; Pérez-Islas E; Hernandez-Peralta ZJ; Toledo-Guzmán ME; García-Carrancá A; Langley E; Hernández-Guerrero A; López-Casillas F; Herrera-Goepfert R; Oñate-Ocaña LF; Ortiz-Sánchez E
Stem Cell Res Ther; 2023 Feb; 14(1):16. PubMed ID: 36737794
[TBL] [Abstract][Full Text] [Related]
3. Lgr5+CD44+EpCAM+ Strictly Defines Cancer Stem Cells in Human Colorectal Cancer.
Leng Z; Xia Q; Chen J; Li Y; Xu J; Zhao E; Zheng H; Ai W; Dong J
Cell Physiol Biochem; 2018; 46(2):860-872. PubMed ID: 29627827
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties.
Wang M; Xiao J; Shen M; Yahong Y; Tian R; Zhu F; Jiang J; Du Z; Hu J; Liu W; Qin R
Int J Cancer; 2011 Jan; 128(1):72-81. PubMed ID: 20232394
[TBL] [Abstract][Full Text] [Related]
5. Identification of gastric cancer stem cells using the cell surface marker CD44.
Takaishi S; Okumura T; Tu S; Wang SS; Shibata W; Vigneshwaran R; Gordon SA; Shimada Y; Wang TC
Stem Cells; 2009 May; 27(5):1006-20. PubMed ID: 19415765
[TBL] [Abstract][Full Text] [Related]
6. Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability.
Guo C; Liu H; Zhang BH; Cadaneanu RM; Mayle AM; Garraway IP
PLoS One; 2012; 7(4):e34219. PubMed ID: 22514625
[TBL] [Abstract][Full Text] [Related]
7. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.
Wei X; Dombkowski D; Meirelles K; Pieretti-Vanmarcke R; Szotek PP; Chang HL; Preffer FI; Mueller PR; Teixeira J; MacLaughlin DT; Donahoe PK
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18874-9. PubMed ID: 20952655
[TBL] [Abstract][Full Text] [Related]
8. Distinct biological characterization of the CD44 and CD90 phenotypes of cancer stem cells in gastric cancer cell lines.
Shu X; Liu H; Pan Y; Sun L; Yu L; Sun L; Yang Z; Ran Y
Mol Cell Biochem; 2019 Sep; 459(1-2):35-47. PubMed ID: 31073886
[TBL] [Abstract][Full Text] [Related]
9. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.
Mitra M; Kandalam M; Harilal A; Verma RS; Krishnan UM; Swaminathan S; Krishnakumar S
Mol Vis; 2012; 18():290-308. PubMed ID: 22328825
[TBL] [Abstract][Full Text] [Related]
10. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells.
Lau WM; Teng E; Chong HS; Lopez KA; Tay AY; Salto-Tellez M; Shabbir A; So JB; Chan SL
Cancer Res; 2014 May; 74(9):2630-41. PubMed ID: 24618343
[TBL] [Abstract][Full Text] [Related]
11. Identification of CD44+CD24+ gastric cancer stem cells.
Zhang C; Li C; He F; Cai Y; Yang H
J Cancer Res Clin Oncol; 2011 Nov; 137(11):1679-86. PubMed ID: 21882047
[TBL] [Abstract][Full Text] [Related]
12. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.
Palagani V; El Khatib M; Kossatz U; Bozko P; Müller MR; Manns MP; Krech T; Malek NP; Plentz RR
PLoS One; 2012; 7(10):e46514. PubMed ID: 23094026
[TBL] [Abstract][Full Text] [Related]
13. Comparison of EpCAM
Liu M; Di J; Liu Y; Su Z; Jiang B; Wang Z; Su X
Cancer Biol Ther; 2018; 19(10):939-947. PubMed ID: 29580161
[TBL] [Abstract][Full Text] [Related]
14. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
[TBL] [Abstract][Full Text] [Related]
16. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
17. A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth.
Park J; Kim SY; Kim HJ; Kim KM; Choi EY; Kang MS
Oncotarget; 2016 May; 7(19):28670-83. PubMed ID: 27107424
[TBL] [Abstract][Full Text] [Related]
18. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
Cioffi M; Dorado J; Baeuerle PA; Heeschen C
Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.
Elkashty OA; Abu Elghanam G; Su X; Liu Y; Chauvin PJ; Tran SD
Carcinogenesis; 2020 Jun; 41(4):458-466. PubMed ID: 31742606
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1.
Bao B; Azmi AS; Aboukameel A; Ahmad A; Bolling-Fischer A; Sethi S; Ali S; Li Y; Kong D; Banerjee S; Back J; Sarkar FH
J Biol Chem; 2014 May; 289(21):14520-33. PubMed ID: 24719318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
